70%,HMG-CoA()HMG-CoA+

HMG-CoAHMG-CoA+ HMG-CoA()+

CRP=C; LDL-C=.Libby P. Circulation. 2001;104:365-372; Ross R. N Engl J Med. 1999;340:115-126.LDL-C

LDL-C LDL-C

8LDL-C LDL-C

LDL-C14%14%3TIA(n=61,324)(n=19,585)47

Dieleman, Current Medical Research and Opinion, 2005: 1461-1468.ASPCFA S P F C 073 vs RR 0.70 95% CI 0.55-0.96)1462192923654385115846577300.860.880.900.920.940.960.981.00

Pfizer Internal UseHPS+

ACSCHDMIRACL+PROVE IT+ARMYDA-ACS+ARMYDA-RECAPTURE+NAPLES II+GREACE+ALLINCE+TNT+IDEAL+ASCOT+CARDS+SPARCL+4S+JUPITER+PACT-LIPID+ CARE+WOSCOPS+ALLHAT-LLT-FLORIDA-LIPS+

Pfizer Internal Use

()LDL-CCURVESNASDACPediatrics StudyALLIANCEASCOT-LLAASPENAVERTCARDS4DTNTIDEALMIRACLSPARCLGREACE*PROVE IT*ARMYDAASAPBELLSREVERSALSAGETREADMILLVascular BasisARBITER*ADCLTBONESLEADeASCOT-LLATNTPROVE IT*MIRACLTNTCARDSPROVE IT**ARBITERGREACEPROVE ITLDL-C

Braunwald Braunwald E, MDBraunwald E, et al. AJC. 2005;96[suppl]:1F-2F

= *

Ray KK, Cannon CP. Crit Pathways in Cardiol . 2005;4: 4345Ray KK, Cannon CP. Expert Opin. Pharmacother. (2005) 6(6):915-927 Probstfield JL, et al. JAMA. 2002;288:2998-3007

SATURN

LDL-Cmg/dl%Nicholls SJ, et al. N Engl J Med 2011;365:2078-87.

80mg40mgLDL-Cmg/dl119.9120P

ENHANCEJohn J.P. Kastelein et al. N Engl J Med 2008;358:1431-43LDL-C(mg/dl)CIMTCIMTmm+LDL-Cmg/dl317319P

Mason RP, et al. Am J Cardiol 2005;96[suppl]:11F23F.Hermann M, et al. Anal Bioanal Chem (2005) 382: 12421249

95%5%. Merck Sharp & Dohme (Australia) Pty. Ltd

90%N..Walter MF et al. J Am Coll Cardiol. 2004;43(suppl A):529A. Abstract 882-4.

**-1001020304050 oxLDL%Mason et al. JACC 49(9):336A;1997

* p < 0.01 vs. Trolox-40-200204060 *Mason RP et al. Journal of Biological Chemistry 2006;281:9337-9345. Mason RP et al. American Journal of Cardiology. 2006;98[suppl]:34P-41P .

WHO 2007

200735(5):390-409

LDL-C4555HDL-C1. ,. 2007;35(5):390-419.2. KDOQI Guidelines for Diabetes and Chronic Kidney Disease AJK D. 2007;49(suppl 2):S1-S1793. 2011 ESC/EAS Guidelines on dyslipidaemias. EHJ ,2011,32:1769-18182007

LDL-C(ACS)2.07mmol/L (80 mg/dl)/2.07mmol/L (80 mg/dl) 2.59 mmol/L (100 mg/dl)/(TIA) 2.59 mmol/L (100 mg/dl)2.59 mmol/L (100 mg/dl)32.59 mmol/L (100 mg/dl)1-4CKD22.59 mmol/L (100 mg/dl)

PROVE IT-PCIPCI80mg/2CVJ Am Coll Cardiol 2009;54:2290540mg/d80mg/d5%10%15%20%30%0%0120240360720480(60025%22%P

TNT-PCIPCI80mg/5CVAm J Cardiol 2008;102:1312131721%P=0.008PCICV%

ACSCVACS (N=1,321)(80mg/d)1227mg/d40mg/d80mg/d24mg/d327(58.7%)87(15.6%)47(7.3%)102(18.4%)*170%P=0.004)*AMIInternational Journal of Cardiology 2010 online

International Journal of Cardiology 2010 onlineHR95%CI

Law MR. BMJ, 2003;326:1423--- 587635971962LDL-C%(%)

Newman CB, et al. Am J Cardiol 2003;92:670676.Newman CB, et al. Am J Cardiol 2006;97:6167. 20079 . . 24449 .

,

Am J Cardiol 2006;97[suppl]:77C81C(NLA)

1/100

2012 FDAhttp://www.fda.gov/Drugs/DrugSafety/ucm293101.htm

2005CirculationFDAAlsheikh-Ali AA, et al. Circulation. 2005;111:3051-3057.20031012004930FDA

Alsheikh-Ali AA, et al. Circulation. 2005;111:3051-3057./P

Alsheikh-Ali AA, et al. Circulation. 2005;111:3051-3057.//P

2010FDASFDA20mg20mg

National Kidney Foundation. Am J Kidney Dis. 2007;49(suppl 2):S1-S180.

Am J Cardiol 2006;97[suppl]:77C81C)Am J Cardiol 2006;97[suppl]:44C51C)(30.8 )

Connie Newman, et al. Am J Cardiol 2006;97:6167Waters DD, Am J Cardiol 2005;96[suppl]:69F75FNKF K/DOQI GUIDELINES 2003

BMJ 2003: 326;17LDL-C 40% 20mg

5 mg10 mg20 mg40 mg80 mg31%37%43%49%55%10%15%21%27%33%--21%29%37%45%15%20%24%29%33%23%27%32%37%42%

ASAP-ENHANCE-REVERSAL-ASTEROID+METEOR+COSMOS+

HPS+

ACS CHDMIRACL+PROVE IT+ARMYDA-ACS+ARMYDA-RECAPTURE+NAPLES II+GREACE+ALLINCE+TNT+IDEAL+ASCOT+CARDS+SPARCL+X 4S+ XX XJUPITER+XPACT-LIPID+ CARE+WOSCOPS+ALLHAT-LLT-XFLORIDA-LIPS+XX

* 6ASCOT-LLACARDSTNTIDEALPROVE ITSPARCLNCEPAHA/ACCADANKFAHA/ASA1. Grundy SM, et al. Circulation. 2004;110:227-239 2. Smith SC, et al. Circulation. 2006;113:2363-2372 3. AMERICAN DIABETES ASSOCIATION. Diabetes Care. 2007;30(S1):S4-S41 4. National Kidney Foundation. Am J Kidney Dis. 2007;49(S2):S12-S154 5. Adams RJ, et al. Stroke. 2008;39

13

4

3 6*

1

0

**

70%HMG-CoAHMG-CoAHMG-CoA*HMG-CoALDL-C*LDL-CLDL-CLDLLDLLDL1,3

References: 1. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation. 2002;105:1135-1143. 2. Al Suwaidi J, Hamasaki S, Higano ST, et al. Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction. Circulation. 2000;101:948-954. 3. Ross R. Atherosclerosisan inflammatory disease. N Engl J Med. 1999;340:115-126. 4. Libby P. Current concepts of the pathogenesis of the acute coronary syndromes. Circulation. 2001;104:365-372.

**LDL-C LDL-C*80,0004761,32419,58563177LDL-CLDL-C14 *349979738%20mg33%10mg23%40mg5.5%10mg30%95% 0.55-0.96

**ACS CHD* LDL-C2005Braunwald *

20102.330082003406

*ACS

1-2ACS6-81-4

*SATURN103980mg/40mg/104LDL-C7.1%7.5%LDL-C

**ENHANCELDL-C72080mg/+10mg/80mg/+2LDL-C(58% vs. 41%P10ULN>3ULN *70%

* 20064NLA

**** LDL-CLDL-C LDL-C 20mg40mgLDL-C40%LDL-C80mgLDL-C40%LDL-C40%20mgLDL-C48%

164638,000LDL-C

2

ACS

***ACS CHD* 136NCEP(2004)AHA/ACC(2006)ADA(2007)NKF2005AHA/ASA(2008)41

*LDL-C20mg